Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Fruquintinib × Clear all

Phase

Status

Sponsor Class

Study Type

Observational 1 Interventional 1

Sponsor

Conditions

Breast Neoplasms 8535 Neoplasms 6565 Carcinoma, Non-Small-Cell Lung 4791 Prostatic Neoplasms 4224 Colorectal Neoplasms 3838 Lung Neoplasms 3082 Leukemia, Myeloid, Acute 2603 Neoplasm Metastasis 2594 Multiple Myeloma 2580 Pancreatic Neoplasms 2408 Melanoma 2222 Lymphoma 2169 Ovarian Neoplasms 2167 Carcinoma, Hepatocellular 2077 Stomach Neoplasms 1958 Recurrence 1863 Head and Neck Neoplasms 1754 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1738 Lymphoma, Non-Hodgkin 1725 Leukemia 1708 Brain Neoplasms 1625 Glioblastoma 1522 Colonic Neoplasms 1500 Leukemia, Lymphocytic, Chronic, B-Cell 1470 Rectal Neoplasms 1453 Uterine Cervical Neoplasms 1395 Lymphoma, Follicular 1371 Squamous Cell Carcinoma of Head and Neck 1363 Lymphoma, Large B-Cell, Diffuse 1342 Carcinoma, Renal Cell 1308

Interventions

raltitrexed 1 potassium oxonate 1 gimeracil 1 Tegafur 1 S 1 (combination) 1 HMPL-013 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06427005 2025-01-22

Fruquintinib Plus S-1 and Raltitrexed (RSF) for MCRC

West China Hospital

Phase 2 Recruiting

Fruquintinib

Data powered by HemOnc (CC BY 4.0) Colophon ⚡